Endurant Capital Management’s Heron Therapeutics HRTX Stock Holding History

Endurant Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-165,404	Closed	-$1.51M	–	74
2021 Q4	$1.51M	Buy	+165,404	New	+$1.69M	0.36%	50
2018 Q3	–	Sell	-8,824	Closed	-$343K	–	78
2018 Q2	$343K	Buy	+8,824	New	+$281K	0.15%	60
2015 Q1	–	Sell	-58,100	Closed	-$584K	–	99
2014 Q4	$584K	Buy	+58,100	New	+$474K	0.23%	77

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Endurant Capital Management's HRTX Position: Q1 2022 in Review

Endurant Capital Management sold out of Heron Therapeutics (HRTX) in Q1 2022, closing a stake of 165,404 shares — an estimated $1.51M sold.

Endurant Capital Management first reported a position in HRTX in Q4 2014 and held it in 3 quarters. The position peaked at $1.51M in Q4 2021. 186 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

Endurant Capital Management reported no remaining Heron Therapeutics position as of Q1 2022 after selling out during the quarter.
Endurant Capital Management sold 165,404 Heron Therapeutics shares in Q1 2022, an estimated $1.51M.
Endurant Capital Management first reported a position in Heron Therapeutics in Q4 2014 and held it in 3 quarters.
Endurant Capital Management's Heron Therapeutics position peaked at $1.51M in Q4 2021.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on Endurant Capital Management's 13F filing for Q1 2022, filed 16 May 2022.